Lodenafil carbonate
| Code | Size | Price |
|---|
| TAR-T37325-5mg | 5mg | £724.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lodenafil carbonate, a dimer that acts as a prodrug delivering Lodenafil in vivo, is an orally active phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED)[1][2]. PDE5
CAS:
398507-55-6
Formula:
C47H62N12O11S2
Molecular Weight:
1035.2
Purity:
0.98
SMILES:
CCCC1=NN(C)C2=C1NC(C3=C(C=CC(S(=O)(N4CCN(CCOC(OCCN5CCN(S(=O)(C6=CC(C(NC7=C8N(C)N=C7CCC)=NC8=O)=C(OCC)C=C6)=O)CC5)=O)CC4)=O)=C3)OCC)=NC2=O
References
Glina S, et al. Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med. 2009 Feb;6(2):553-7.
Toque HA, et al. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008 Sep 4;591(1-3):189-95.